Figure 3.

Ablation of Dnmt3a and both Dnmt1 and Dnmt3a impairs oligodendrocyte differentiation during remyelination. A, Representative OLIG2 and CC1 staining at 14 dpl in tamoxifen-treated Plp^{+ /+};Dnmt1^fl/fl and Plp^{creER(t) /+};Dnmt1^fl/fl spinal cords. B, Quantification of OLIG2⁺ and CC1⁺ cell densities and CC1⁺/OLIG2⁺ cells percentage at 14 dpl^l (p = 0.7955, p = 0.3573, p = 0.9689). C, Representative OLIG2 and CC1 staining at 14 dpl in tamoxifen-treated Plp^{+ /+};Dnmt3a^fl/fl and Plp^{creER(t) /+};Dnmt3a^fl/fl spinal cords. D, Quantification of OLIG2⁺ and CC1⁺ cell densities and CC1⁺/OLIG2⁺ cells percentage at 14 dpl^m (p = 0.7851, p = 0.0550, p = 0.0149). E, Representative OLIG2 and CC1 staining at 14 dpl in tamoxifen-treated Plp^{+ /+};Dnmt1^fl/fl;Dnmt3a^fl/fl and Plp^{creER(t) /+};Dnmt1^fl/fl;Dnmt3a^fl/fl spinal cords. F, Quantification of OLIG2⁺ and CC1⁺ cell densities and CC1⁺/OLIG2⁺ cells percentage at 14 dplⁿ (p = 0.1510, p = 0.0357, p = 0.0006). G, Quantification of DNMT1 and DNMT3A expression in CC1⁺ cells at 14 dpl in tamoxifen-treated Plp^{+ /+};Dnmt1^fl/fl and Plp^{creER(t) /+};Dnmt1^fl/fl, Plp^{+ /+};Dnmt3a^fl/fl and Plp^{creER(t) /+};Dnmt3a^fl/fl, Plp^{+ /+};Dnmt1^fl/fl;Dnmt3a^fl/fl and Plp^{creER(t) /+};Dnmt1^fl/fl;Dnmt3a^fl/fl spinal cords, to detect eventual compensation between DNMTs at the protein level° (p = 0.0075, p = 0.0505, p = 0.0074, p = 0.0053, p = 0.0072, p = 0.0012). Scale bar = 20 µm. Data are mean ± SEM. n = 4–6 animals, three sections per animal. *p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t test).